Jacc Heart Fail

• 

  Publication Venue For

  • Catheter Ablation of Atrial Fibrillation in Persons With HFpEF: We Can All Breathe Easier Now!.  11:659-661. 2023
  • Hidden Bias: The Intersection of Ageism and Gender in Adult Cardiology..  11:717-719. 2023
  • Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA..  11:583-592. 2023
  • Impact of the 2018 UNOS Heart Transplant Policy Changes on Patient Outcomes..  11:491-503. 2023
  • Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF..  11:569-579. 2023
  • Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum..  11:375-388. 2023
  • Medication-Attributable Adverse Events in Heart Failure Trials..  11:425-436. 2023
  • Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF..  11:392-403. 2023
  • Considering Addition of Acetazolamide to Loop Diuretics as Treatment for Acute Heart Failure: ADVOR Reappraisal..  11:365-367. 2023
  • Advanced Heart Failure in the Cardiac Intensive Care Unit: A Community-Based Study..  11:252-254. 2023
  • Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States..  11:211-223. 2023
  • Impact of COVID-19 on Heart Failure Clinical Trials: Insights From the Heart Failure Collaboratory..  11:254-257. 2023
  • Reply: Blood Pressure and Lack of Association With Treatment Benefits of Dapagliflozin in HFpEF and HFmrEF..  11:261-262. 2023
  • Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER..  11:76-89. 2023
  • Neighborhood Household Income and Trends in 30-Day Readmission for Patients With Heart Failure..  11:121-123. 2023
  • Personalizing Risk Assessment for Sudden Cardiac Death in Heart Failure: A Dream or a Reality?.  11:55-57. 2023
  • Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan..  11:44-54. 2023
  • Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status..  10:976-988. 2022
  • Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel..  10:889-901. 2022
  • Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction..  10:902-913. 2022
  • Obesity Status and Physical Rehabilitation in Older Patients Hospitalized With Acute HF: Insights From REHAB-HF..  10:918-927. 2022
  • Trends in Heart Failure-Related Mortality Among Older Adults in the United States From 1999-2019..  10:851-859. 2022
  • Transvenous Right Greater Splanchnic Nerve Ablation in Heart Failure and Preserved Ejection Fraction: First-in-Human Study..  10:744-752. 2022
  • Are We Getting Any Closer to Understanding Congestion?.  10:633-636. 2022
  • Contemporary Applications of Machine Learning for Device Therapy in Heart Failure..  10:603-622. 2022
  • Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat..  10:677-688. 2022
  • Expenditure on Heart Failure in the United States: A Rising Tide Lifts All Boats..  10:581-582. 2022
  • Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment: Is There a Role for Cardioprotection?.  10:568-570. 2022
  • Hospitalization Patterns and Impact of a Magnetically-Levitated Left Ventricular Assist Device in the MOMENTUM 3 Trial..  10:470-481. 2022
  • Residual Heart Failure on Mechanically Assisted Circulation: A Call to Action..  10:482-484. 2022
  • Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the LIFE Trial Run-In..  10:449-456. 2022
  • Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome..  10:404-414. 2022
  • Reply: Complications and Mortality Following CRT-D vs ICD..  10:444-445. 2022
  • Thank You for the Privilege..  10:441-443. 2022
  • Reply: Revisited Metformin Therapy in Heart Failure With Preserved Ejection Fraction..  10:366-367. 2022
  • Sacubitril/Valsartan Therapy for AF and HFpEF: Is the Glass Half Empty or Half Full?.  10:347-349. 2022
  • Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018..  10:350-362. 2022
  • Editorial Privilege..  10:290. 2022
  • Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial..  10:266-275. 2022
  • Spirituality in Patients With Heart Failure..  10:217-226. 2022
  • Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial..  10:184-197. 2022
  • Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes..  10:198-210. 2022
  • Complications and Mortality Following CRT-D Versus ICD Implants in Older Medicare Beneficiaries With Heart Failure..  10:147-157. 2022
  • Implementation Noise..  10:211-212. 2022
  • Natriuretic Peptides and Stratification for ICD Therapy in Nonischemic Heart Failure: A Definite Maybe?.  10:172-174. 2022
  • Behavioral Benefits of COVID Lockdown for Heart Failure Patients: A New Therapeutic Intervention?.  10:142-143. 2022
  • Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults..  10:129-138. 2022
  • Cost and Value in Contemporary Heart Failure Clinical Guidance Documents..  10:1-11. 2022
  • Rinse, Wash, Repeat: The Evolution of the UNOS Heart Transplant Allocation System..  10:24-26. 2022
  • Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure..  9:890-903. 2021
  • Look After You Leap..  9:925-926. 2021
  • Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction..  9:876-886. 2021
  • Long-Term Neurocognitive Outcome in Patients With Continuous Flow Left Ventricular Assist Device..  9:839-851. 2021
  • Classifying Heart Failure in the 21st Century: Matching Taxonomy With Science..  9:771-773. 2021
  • Missing the True Target in Advanced Heart Failure: It Is Time to Look in the Mirror..  9:733-735. 2021
  • Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD)..  9:758-767. 2021
  • Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction..  9:747-757. 2021
  • Don't Be So Fast to Discard That Clean Catch!.  9:624-626. 2021
  • From Clinical Trials to Communities: The 5 C's of Ensuring Equitable Delivery of Heart Failure Therapies..  9:694-696. 2021
  • Practical and Evidence-Based Approaches to In-Hospital Decongestion for Heart Failure: Are We There Yet?.  9:649-652. 2021
  • Empower the Future… Even Oprah Had a Mentor!.  9:604-605. 2021
  • Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial..  9:568-577. 2021
  • Reply: Pragmatic Clinical Trials: The Big Picture..  9:606-608. 2021
  • Change Is the Only Constant in Heart Failure..  9:528-529. 2021
  • Function Follows Form..  9:482-483. 2021
  • Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure..  9:497-505. 2021
  • Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults..  9:484-493. 2021
  • Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure..  9:471-481. 2021
  • Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy..  9:420-429. 2021
  • Device Development in the Gray Zone: One Step Forward..  9:463-464. 2021
  • Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial..  9:325-335. 2021
  • Promoting Diversity in Clinical Trial Leadership: A Call to Action..  9:401-402. 2021
  • Reply: Optimal Positioning of Novel Heart Failure Pharmacotherapies: The Case of Vericiguat..  9:403. 2021
  • Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure..  9:336-345. 2021
  • Worsening Heart Failure Events in HFpEF: Underlying Biology Not Treatment Location..  9:383-385. 2021
  • Heart Failure Leadership, Culture, and Governance: Lessons Learned From Tom Brady..  9:317-318. 2021
  • Reply: Improving Heart Failure Therapeutics: Thinking Outside the Pillbox?.  9:320-321. 2021
  • Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure..  9:293-300. 2021
  • Reviewers Hall of Fame: 2020 Top Reviewers..  9:241. 2021
  • Setting the Stage for a Multimarker-Based Heart Failure Prevention Trial?.  9:224-225. 2021
  • Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction..  9:127-136. 2021
  • Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study..  9:146-157. 2021
  • Meet Me in the Middle: Lessons From the Cardiorenal Advisory Committee for Sacubitril/Valsartan in HFpEF..  9:161-163. 2021
  • Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes..  9:137-145. 2021
  • A Generation Passed; A Generation Forward: Why Joseph C. Greenfield, Chairman of Medicine, Duke University, Matters Today (1931 to 2020)..  9:80-81. 2021
  • Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients..  9:28-38. 2021
  • Putting the "Optimal" in Optimal Medical Therapy..  9:39-41. 2021
  • Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory..  9:1-12. 2021
  • Aldosterone: Behind the Scenes of Depression and Heart Failure?.  8:1021-1023. 2020
  • Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2..  8:999-1008. 2020
  • Changing U.S. Heart Failure Research Culture: Part 2-Recognizing Frontline Investigators and Coordinators..  8:1050-1051. 2020
  • Home Health Care Use and Post-Discharge Outcomes After Heart Failure Hospitalizations..  8:1038-1049. 2020
  • Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium..  8:961-972. 2020
  • Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation..  8:973-983. 2020
  • In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States..  8:943-953. 2020
  • N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study..  8:931-939. 2020
  • Personalized Therapeutic Approach: Gun Control for Shotgun Therapy..  8:954-955. 2020
  • Reply: Heart Transplant Allocation Under New Policy: Perceived Risk and Gaming the System..  8:958-959. 2020
  • Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial..  8:859-866. 2020
  • Convalescence From COVID Research: Lessons From the Heart Failure Community..  8:870-871. 2020
  • Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial..  8:834-843. 2020
  • Medications Are Important for Sudden Cardiac Death Prevention But So Is the Implantable Cardioverter-Defibrillator..  8:856-858. 2020
  • Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial..  8:789-799. 2020
  • Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis..  8:712-724. 2020
  • Reply: Temporary Mechanical Circulatory Support as a Bridge to Transplantation: Return of the Intra-Aortic Balloon Pump..  8:786-787. 2020
  • Splanchnic Nerve Block for Chronic Heart Failure..  8:742-752. 2020
  • The Journey of an American Black Cardiologist..  8:780-781. 2020
  • The Maximally Tolerated Dose: The Key Context for Interpreting Subtarget Medication Dosing for Heart Failure..  8:739-741. 2020
  • Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community..  8:640-653. 2020
  • Heart Failure Collaboratory Statement on Remote Monitoring and Social Distancing in the Landscape of COVID-19..  8:692-694. 2020
  • Advanced Heart Failure: Epidemiology, Diagnosis, and Therapeutic Approaches..  8:523-536. 2020
  • COVID-19 Fatigue: Not So Fast..  8:592-594. 2020
  • Heart Transplantation: An In-Depth Survival Analysis..  8:557-568. 2020
  • Reassessing Recipient Mortality Under the New Heart Allocation System: An Updated UNOS Registry Analysis..  8:548-556. 2020
  • Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry..  8:469-480. 2020
  • Endpoints in Heart Failure Drug Development: History and Future..  8:429-440. 2020
  • Heart Failure Outcomes and Associated Factors Among Veterans With Human Immunodeficiency Virus Infection..  8:501-511. 2020
  • Biomarkers of Congestion: Emerging Tools in the Management of Heart Failure?.  8:398-400. 2020
  • Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19..  8:423-425. 2020
  • Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper..  8:347-358. 2020
  • Association of Implantable Device Measured Physical Activity With Hospitalization for Heart Failure..  8:280-288. 2020
  • Heart Failure Multidisciplinary Teams and New Zealand Rugby: What Can We Learn From the "All Blacks" Rugby Team?.  8:341-342. 2020
  • Old Device, New Tricks: Exploring Axillary Intra-Aortic Balloon Pump Use in Advanced Heart Failure..  8:324-326. 2020
  • Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF..  8:329-340. 2020
  • Is Resistance Futile?: Addressing Diuretic Resistance During Hospitalization for Heart Failure..  8:169-171. 2020
  • Suicide in HF Patients: A Call for Recognition..  8:243-244. 2020
  • Durability and Efficacy of Tricuspid Valve Repair in Patients Undergoing Left Ventricular Assist Device Implantation..  8:141-150. 2020
  • Healthy Aging and Cardiovascular Function: Invasive Hemodynamics During Rest and Exercise in 104 Healthy Volunteers..  8:111-121. 2020
  • Open Access in Heart Failure: Ready or Not, Here We Come..  8:151-152. 2020
  • Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction..  8:70-80. 2020
  • From Theory to Practice: The Use of Real-World Data to Evaluate New Heart Failure Therapies..  8:55-56. 2020
  • The Heart Failure High Five: Medical Therapy and Policy: 2019..  8:81-82. 2020
  • The Hospital Readmissions Reduction Program: Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper..  8:1-11. 2020
  • Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction..  7:1029-1031. 2019
  • Frailty Among Older Decompensated Heart Failure Patients: Prevalence, Association With Patient-Centered Outcomes, and Efficient Detection Methods..  7:1079-1088. 2019
  • Heart Failure Prevention in Older Patients Using Intensive Blood Pressure Reduction: Potential Role of Diuretics..  7:1032-1041. 2019
  • Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction..  7:1056-1065. 2019
  • N-1 and Sequencing Clinical Heart Failure Trials: Charting the Path for Future Clinical Care..  7:1089-1090. 2019
  • A Call for Change: Level of Statistical Significance..  7:993-994. 2019
  • Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction..  7:933-941. 2019
  • Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development..  7:913-921. 2019
  • Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality..  7:970-979. 2019
  • Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF..  7:980-992. 2019
  • The Future of Wearables in Heart Failure Patients..  7:922-932. 2019
  • Acute Decompensated Heart Failure: Is There a Path Forward?.  7:911-912. 2019
  • CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial..  7:878-887. 2019
  • ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure..  7:907-910. 2019
  • Real-World Evidence for Medication Safety: Causal, Confounded, or Capable?.  7:846-848. 2019
  • Diastolic Function in Heart Failure With Reduced Ejection Fraction: The Overlooked Prognosticator?.  7:818-820. 2019
  • Heart Failure Physician Burnout: How Can We Help?.  7:821. 2019
  • Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Cardiomyopathy..  7:725-727. 2019
  • Why Should We Publish All Clinical Trials?.  7:730. 2019
  • Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF..  7:615-625. 2019
  • Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial..  7:586-598. 2019
  • N-of-1 Clinical Trials..  7:630-631. 2019
  • Reply: Heart Failure With Preserved Ejection Fraction: Types 1 and 2?.  7:632-633. 2019
  • Better Quality of Life Over More Quantity of Life: How We View Time Trade-Off..  7:531-532. 2019
  • Heart Failure and Atrial Fibrillation, Like Fire and Fury..  7:447-456. 2019
  • Sex-Based Differences in Outcomes After Mitral Valve Surgery for Severe Ischemic Mitral Regurgitation: From the Cardiothoracic Surgical Trials Network..  7:481-490. 2019
  • Guideline-Directed Medical Therapy Clinics: A Call to Action for the Heart Failure Team..  7:442-443. 2019
  • Heart Failure Site-Based Research in the United States: Results of the Heart Failure Society of America Research Network Survey..  7:431-438. 2019
  • Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease..  7:371-382. 2019
  • Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction..  7:418-427. 2019
  • Heart Failure Fake News: How Do We Distinguish the Truth?.  7:363. 2019
  • Reframing Global Variation in Heart Failure Trials: Thinking Beyond Location on the Map..  7:347-349. 2019
  • Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry..  7:350-358. 2019
  • Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials?.  7:267-271. 2019
  • Heart Failure in Women..  7:274-275. 2019
  • Primary Prevention of Heart Failure in Women..  7:181-191. 2019
  • Cardiac Dysfunction Among People Living With HIV: A Systematic Review and Meta-Analysis..  7:98-108. 2019
  • NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF..  7:158-168. 2019
  • Recognizing Heart Failure Awareness Week..  7:173. 2019
  • History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure..  7:47-55. 2019
  • Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization..  7:1-12. 2019
  • JACC: Heart Failure Peer Review Hall of Fame 2018..  7:81. 2019
  • Potassium Abnormalities Across the Spectrum of Heart Failure..  7:77-79. 2019
  • Reply: Vaccination in Patients With Heart Failure: An Established Recommendation in Patients With Chronic Heart Disease..  7:85. 2019
  • The Urgency of Doing: Addressing Gaps in Use of Evidence-Based Medical Therapy for Heart Failure..  7:22-24. 2019
  • Aviation Emergencies for Heart Failure Cardiologists: A New Twist to the Heart Team..  6:1047-1048. 2018
  • Influence of Baseline Physical Activity Level on Exercise Training Response and Clinical Outcomes in Heart Failure: The HF-ACTION Trial..  6:1011-1019. 2018
  • Reply: Diuretic Strategies and Renal Dysfunction in Heart Failure With Preserved Ejection Fraction..  6:1050. 2018
  • COAPTing Heart Failure Physicians, Interventional Cardiologists, and CardioThoracic Surgeons: A New Opportunity for Patients..  6:967-968. 2018
  • Caregivers of Patients Considering a Destination Therapy Left Ventricular Assist Device and a Shared Decision-Making Intervention: The DECIDE-LVAD Trial..  6:904-913. 2018
  • Is it Time to Get More Aggressive With Aortic Valve Insufficiency During LVAD Implantation?.  6:961-963. 2018
  • Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus..  6:813-822. 2018
  • Combating Acute Heart Failure in the Arena: Lessons From the ROPA-DOP Trial..  6:871-873. 2018
  • Depression in Heart Failure: Beyond a SADHART..  6:885-886. 2018
  • Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial..  6:833-843. 2018
  • Preventing Heart Failure in Diabetes: Glycemic Targets or Class Effect?.  6:831-832. 2018
  • Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial..  6:859-870. 2018
  • Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure..  6:844-855. 2018
  • A Bayesian Model to Predict Survival After Left Ventricular Assist Device Implantation..  6:771-779. 2018
  • HVAD: The ENDURANCE Supplemental Trial..  6:792-802. 2018
  • It Is Time to Discuss Dying..  6:790-791. 2018
  • Politically Correct Heart Failure Research in America to Avoid Geographic Variation..  6:805-806. 2018
  • Predicting Prognosis in Heart Failure: Important, But Easier Said Than Done..  6:754-756. 2018
  • Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction: A Systematic Review..  6:714-717. 2018
  • HFpEF: From Early Observations to Worldwide Awareness..  6:718-719. 2018
  • Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials..  6:619-632. 2018
  • Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF: Preserving Hope..  6:698-700. 2018
  • Regional Adipose Distribution and its Relationship to Exercise Intolerance in Older Obese Patients Who Have Heart Failure With Preserved Ejection Fraction..  6:640-649. 2018
  • Cardiovascular Drug Pricing: Less Innovation for More Access?.  6:613-614. 2018
  • Dying With Dignity and Heart Failure: A Lesson From Barbara Bush..  6:536-537. 2018
  • Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure..  6:465-473. 2018
  • Revascularization for Heart Failure: Can We Do Better?.  6:527-529. 2018
  • Traveling the Interstices of Data Sharing..  6:533-535. 2018
  • Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure With Preserved Ejection Fraction..  6:388-397. 2018
  • What's One More Day?.  6:438. 2018
  • "Time Is Muscle" in Acute Heart Failure: Critical Concept or Fake News?.  6:295-297. 2018
  • Changing the Research Culture in the United States..  6:344-345. 2018
  • Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial..  6:298-307. 2018
  • Heart Failure Health Care 2018: Challenges and Opportunities..  6:262-263. 2018
  • Post-Myocardial Infarction Heart Failure..  6:179-186. 2018
  • Reply: Efficacy of Subcutaneous vs. Intravenous Administration of Furosemide in Patients With Worsening Heart Failure: The Devil Is in the Details..  6:267. 2018
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial..  6:96-104. 2018
  • Are We Approaching Chronotropy (In)competently?.  6:114-116. 2018
  • Cardiac Rehabilitation After Ventricular Assist Device Implantation: A Worthwhile Exercise?.  6:140-142. 2018
  • Smartphone, Mom, and HFpEF..  6:176. 2018
  • Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure..  6:65-70. 2018
  • I Don't Care How Low My BNP Is, I Want to Feel Good..  6:82-83. 2018
  • Happy 50th Birthday, Cardiac Transplantation: Happy 5th Birthday, JACC: Heart Failure..  5:946-947. 2017
  • Implantable Cardioverter-Defibrillators in Patients With Left Ventricular Assist Devices: On Trial and in Need of a Trial..  5:927-929. 2017
  • Goodbye Mihai: We Will Miss You..  5:848-849. 2017
  • Realizing the Potential of Metabolomics in Heart Failure: Signposts on the Path to Clinical Utility..  5:833-836. 2017
  • Q&A With the JACC: Heart Failure Editor-in-Chief: Marking the 5-Year Milestone..  5:758-759. 2017
  • The Risk of Stroke on Left Ventricular Assist Device Support: Steady Gains or Stalled Progress?.  5:712-714. 2017
  • Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study..  5:724-734. 2017
  • America and Apple Pie: How Do We Change the American Health Care System?.  5:686-687. 2017
  • Discordant Perceptions of Prognosis and Treatment Options Between Physicians and Patients With Advanced Heart Failure..  5:663-671. 2017
  • Medical Management of Patients With a Left Ventricular Assist Device for the Non-Left Ventricular Assist Device Specialist..  5:621-631. 2017
  • Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types..  5:689. 2017
  • Does Institutional Memory Matter?.  5:616. 2017
  • A Decade With Editorial Mentors: The Day They Dropped the Mic..  5:541-542. 2017
  • Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction..  5:507-517. 2017
  • Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction..  5:483-493. 2017
  • Breaking Bad: The Heartbreak of Drug Abuse..  5:446-448. 2017
  • Development of Acute Decompensated Heart Failure Therapies: Is the Journey Over?.  5:464-465. 2017
  • A Novel Rehabilitation Intervention for Older Patients With Acute Decompensated Heart Failure: The REHAB-HF Pilot Study..  5:359-366. 2017
  • Acute Heart Failure: Alternatives to Hospitalization..  5:329-336. 2017
  • High Heart Failure Readmission Rates: Is It the Health System's Fault?.  5:393. 2017
  • Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy..  5:388-392. 2017
  • Data Sharing From the Editors' Perspective: Our Hope With Limitations..  5:314-315. 2017
  • Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF)..  5:305-309. 2017
  • Moving Beyond the Walls of the Clinic: Opportunities and Challenges to the Future of Telehealth in Heart Failure..  5:297-304. 2017
  • Reply: Factors That May Affect Body Change During and After Hospitalization for Acute Heart Failure..  5:311-312. 2017
  • Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions..  5:194-203. 2017
  • Easy to Predict, Difficult to Prevent..  5:226-228. 2017
  • Is Salt Bad for You?.  5:238-239. 2017
  • JACC: Heart Failure Series: FDA in the 21st Century: Focus on Nutrition and Heart Failure Prevention..  5:229-231. 2017
  • Return on Investment in Implantable Devices: Cardiac Resynchronization Therapy in Mildly Symptomatic Heart Failure..  5:213-215. 2017
  • 21st Century Cures: A Step Forward for Patients With Heart Failure..  5:154. 2017
  • FDA in the 21st Century: Focus on Tobacco Policies and Heart Failure Prevention..  5:152-153. 2017
  • Heart Failure Complicated by Atrial Fibrillation: Don't Bury the Beta-Blockers Just Yet..  5:107-109. 2017
  • Optimism, Pessimism, and Pragmatism: Musings on the Cost of Medical Innovation..  5:120-122. 2017
  • Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial..  5:1-13. 2017
  • Developing Breakthrough Drugs for Heart Failure: Lessons Learned From the Cystic Fibrosis Experience..  5:71-72. 2017
  • Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis..  5:28-38. 2017
  • Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation..  5:44-52. 2017
  • The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development..  5:67-70. 2017
  • Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes..  4:935-946. 2016
  • Not Your Mother's FDA..  4:978. 2016
  • Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations..  4:923-931. 2016
  • The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Heart Failure Devices..  4:974-977. 2016
  • Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial..  4:860-869. 2016
  • Left Bundle Branch Block: Is it "Unsafe at Any Speed"?.  4:904-906. 2016
  • Peer Review of Peer Review: Somewhere Over the Rainbow..  4:907-908. 2016
  • The International Olympic Games: Heart Teams and Heart Failure..  4:826-827. 2016
  • Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease?.  4:689-697. 2016
  • Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure..  4:726-735. 2016
  • The Mentor's Mentor: The Life of Galen Wagner..  4:759. 2016
  • Can Academic Cardiology Divisions Survive?.  4:687-688. 2016
  • Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION..  4:617-624. 2016
  • Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program..  4:649-661. 2016
  • Brain Natriuretic Peptide Treatment and Heart Failure Prevention: Reliving the Mistakes of the Past or Charting a New Course for the Future?.  4:548-550. 2016
  • Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction..  4:559-566. 2016
  • The Year in Heart Failure Review 2015 to 2016..  4:603-604. 2016
  • Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial..  4:591-599. 2016
  • Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps..  4:419-427. 2016
  • Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction..  4:464-472. 2016
  • Prolonged QRS in Heart Failure With Preserved Ejection Fraction: Risk Marker and Therapeutic Target?.  4:487-489. 2016
  • Social Media: Can It Reduce Heart Failure Events?.  4:514-515. 2016
  • Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study..  4:380-388. 2016
  • Are We Really in Love With Old Therapies? 2016
  • Why Negative Trials Are Positive for Heart Failure Patients..  4:329-330. 2016
  • A Machine Without an Owner's Manual..  4:218-219. 2016
  • I Lost a Friend From HFpEF: William Anlyan, MD, Chancellor Emeritus and Duke University Trustee..  4:230-231. 2016
  • Utility of Patient-Reported Outcome Instruments in Heart Failure..  4:165-175. 2016
  • Death of the Heart Failure Clinical Investigator: Molecules and Receptors Win Nobel Prizes, Clinical Investigation Improves Survival..  4:162-163. 2016
  • Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial..  4:109-115. 2016
  • When Business and Science Clash, How Can We Avoid Harming Patients?: The Case of AVOID-HF..  4:106-108. 2016
  • Air Pollution in Patients With Heart Failure: Lessons From a Mechanistic Pilot Study of a Filter Intervention..  4:65-67. 2016
  • Association of Arterial Pulse Pressure With Long-Term Clinical Outcomes in Patients With Heart Failure..  4:42-49. 2016
  • Back to the Future With Intravenous Diuretics: Reinvigorating an Old Treatment Through New Care Settings..  4:9-11. 2016
  • Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure..  4:68-77. 2016
  • Reply: Is Pump the Answer to Heart Failure With Preserved Ejection Fraction?.  4:93. 2016
  • Why Dr. Robert Califf's Nomination for Commissioner of the Food and Drug Administration Is Good for Heart Failure Patients..  4:90-91. 2016
  • Heart Failure "End Result Cards": Solid B..  3:1001-1002. 2015
  • Bundle Up for Value-Based Heart Failure Care..  3:931-932. 2015
  • Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy..  3:906-916. 2015
  • Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)..  3:777-785. 2015
  • Fibroblast Growth Factor-23 Fans the Flames of Heart and Kidney Failure..  3:840-842. 2015
  • Identification of Emergency Department Patients With Acute Heart Failure at Low Risk for 30-Day Adverse Events: The STRATIFY Decision Tool..  3:737-747. 2015
  • Physician-Leaders: A Call for Cardiovascular Specialists to Step Up..  3:843-844. 2015
  • The HVAD Left Ventricular Assist Device: Risk Factors for Neurological Events and Risk Mitigation Strategies..  3:818-828. 2015
  • What's Harder: Seeing a Doctor or Reducing Readmissions?.  3:774-776. 2015
  • "Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction..  3:661-669. 2015
  • Changing the Carburetor Without Changing the Plugs: The Intersection of Stock Car Racing With Mechanically Assisted Circulation..  3:712-714. 2015
  • What Is a Life Worth?: A Tribute to Dr. William Little, a Pioneer in the Understanding of Heart Failure With Preserved Ejection Fraction..  3:734-735. 2015
  • Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries..  3:579-590. 2015
  • The Globalization of Heart Failure Research..  3:657-658. 2015
  • Why We Respect Randomized Controlled Clinical Trials in Heart Failure..  3:576-577. 2015
  • Cardiac Resynchronization Therapy in the Autumn of Life..  3:505-507. 2015
  • Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?.  3:497-504. 2015
  • Hospitalizations and Prognosis in Elderly Patients With Heart Failure and Preserved Ejection Fraction: Time to Treat the Whole Patient..  3:442-444. 2015
  • Time for Recognition..  3:508-509. 2015
  • Medical editors' grand rounds: a discussion of timely topics and editorial emergencies..  3:422-423. 2015
  • Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies..  3:395-403. 2015
  • Left atrial decompression pump for severe heart failure with preserved ejection fraction: theoretical and clinical considerations..  3:275-282. 2015
  • Reading RVUs: How can we meet the informational needs of cardiologists?.  3:340-341. 2015
  • Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure)..  3:245-252. 2015
  • Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure)..  3:193-201. 2015
  • Hop, skip, and jump: do we need phase II cardiovascular clinical trials?.  3:273-274. 2015
  • Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure..  3:97-107. 2015
  • Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure..  3:136-145. 2015
  • Primary prevention implantable cardioverter-defibrillators and survival in older women..  3:159-167. 2015
  • War and peace: the role of medical journals in the discussion of conflict..  3:192. 2015
  • Biomarkers, mineralocorticoid receptor antagonism, and cardiorenal remodeling..  3:68-69. 2015
  • Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial..  3:40-49. 2015
  • Conflict of interest and transparency: are the headlights misaligned?.  3:94. 2015
  • Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury..  3:30-39. 2015
  • The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease..  3:9-16. 2015
  • Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials..  2:623-629. 2014
  • Precision and predictive medicine: lessons learned from our oncology colleagues..  2:671. 2014
  • Race, common genetic variation, and therapeutic response disparities in heart failure..  2:561-572. 2014
  • Reply: predicting sudden cardiac death in heart failure..  2:673. 2014
  • Are models better than cardiologists?: An analysis of risk prediction in heart failure..  2:536-537. 2014
  • Can we now find the needle in the haystack?.  2:474-476. 2014
  • Charting a roadmap for heart failure biomarker studies..  2:477-488. 2014
  • Chronic counterpulsation devices for heart failure..  2:534-535. 2014
  • Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure..  2:457-465. 2014
  • Does low bone mineral density cause a broken heart?.  2:390-391. 2014
  • Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure)..  2:335-343. 2014
  • Heart failure: where the paths cross..  2:427. 2014
  • Atrial fibrillation and sudden cardiac death: is heart failure the middleman?.  2:228-229. 2014
  • Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure..  2:260-268. 2014
  • Developing therapies for heart failure with preserved ejection fraction: current state and future directions..  2:97-112. 2014
  • Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)..  2:159-165. 2014
  • Meta-analysis bouillabaisse..  2:201-202. 2014
  • Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives..  2:1-14. 2014
  • Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b)..  2:84-92. 2014
  • Design of design papers..  2:95-96. 2014
  • Outcomes of medicare beneficiaries with heart failure and atrial fibrillation..  2:41-48. 2014
  • Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States..  1:523-530. 2013
  • It is time to exercise change for heart failure..  1:549-550. 2013
  • The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial..  1:488-496. 2013
  • Associations between use of the hospitalist model and quality of care and outcomes of older patients hospitalized for heart failure..  1:445-453. 2013
  • JACC: Heart Failure fellows program: training the next generation..  1:458. 2013
  • The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results..  1:400-408. 2013
  • DUCCS and SWANS: when U.S. site-based research was highly successful..  1:366-367. 2013
  • Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2)..  1:308-314. 2013
  • Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism..  1:338-344. 2013
  • Racial/Ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure..  1:345-352. 2013
  • Do we really need more biomarkers?.  1:270-271. 2013
  • Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes..  1:223-229. 2013
  • Left bundle branch block predicts better survival in women than men receiving cardiac resynchronization therapy: long-term follow-up of ∼ 145,000 patients..  1:237-244. 2013
  • Surfing the biomarker tsunami at JACC: heart failure..  1:213-215. 2013
  • Validated, electronic health record deployable prediction models for assessing patient risk of 30-day rehospitalization and mortality in older heart failure patients..  1:245-251. 2013
  • Dead letter office..  1:181-182. 2013
  • Exercise training and implantable cardioverter-defibrillator shocks in patients with heart failure: results from HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing)..  1:142-148. 2013
  • Thyroid function in heart failure and impact on mortality..  1:48-55. 2013
  • Why JACC: heart failure?.  1:91. 2013
  • Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. 2021
  • Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. 2017
  • Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. 2016